Carregant...
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proo...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4801439/ https://ncbi.nlm.nih.gov/pubmed/27057434 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1069939 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|